Clinical Studies

Clinical research studies are vital to the process of discovering the safest and most effective cancer therapies for patients. The C.R. Wood Cancer Center currently has approximately 40 national clinical studies available for treatment, quality of life and prevention of different cancers. Glens Falls Hospital has partnered with the University of Vermont for shared opportunities in their clinical studies, and the center also participates in clinical studies directly through pharmaceutical companies. The physicians and staff of the C.R. Wood Cancer Center work closely with these well respected organizations, along with the National Cancer Institute, to provide opportunities for local patients to take part in national clinical research studies, without having to travel away from home. These studies provide the opportunity for patients to conveniently receive some of the most cutting edge therapies available, while also allowing them to directly contribute to the ongoing progress being made in the field of oncology. Treatment studies may consist of chemotherapy, immunotherapy, radiation therapy, hormonal therapy or combination therapy. More than 300 patients have participated in clinical studies at the Cancer Center over the past five years.

For More information on clinical studies, contact Beth Ann Brundage, RN, OCN, at (518) 926-6644 or Nannette Oberhelman, at (518) 926-6701.

Clinical Trials: Breast

CTSU NRG-BR003

  • Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

PUMA NER 1301

  • (NALA) A Study of Neratinib Plus Capecitabine vs. Lapatinib Plus Capecitabine in Patients with Her2+ Metastatic Breast Ca who Have Received >/= 2 Prior Her2-Directed Regimens in the Metastatic Setting


Clinical Trials: Head and Neck

CTSU RTOG 0920

  • A Phase III Study of Postoperative Radiation Therapy (IMRT) =/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer


Clinical Trials: Leukemia

P TG UTX-TGR-204

  • A Multi-Center, Open-Label, Study to Evaluate the Safety & Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

P TG UTX-TGR-304

  • A Phase 3, Randomized Study to Assess the Efficacy & Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)


Clinical Trials: Lung

CTSU EAY131 (MATCH)

  • Molecular Analysis for Therapy Choice; Screening for Treatment Assignment Based on Genetic Testing

SCLC Limited

C 30610

  • Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

NSCLC Limited

CTSU A151216 NSCLC

  • Genetic Testing For Patients with Resectable or Resected Lung Cancer (ALCHEMIST)

CTSU E4512

  • A Phase III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib vs. Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. (ALCHEMIST)

CTSU EA5142

  • Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (ALCHEMIST)

CTSU A081105 Alchemist

  • A Phase III Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant NSCLC (ALCHEMIST)

P BMS CA209370 CheckMate

  • A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies (Only Group D remains open)


Clinical Trials: Multiple Myeloma

P Celgene CC-4047-MM-014

  • A Phase 2, Multicenter, Multi-Cohort, Open-Label Study of Pomalidomide in Combination with Low -Dose Dexamethasone or Pomalidomide in Combination with Low -Dose Dexamethasone and Daratumumab in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based therapy in the First or Second Line Setting


Clinical Trials: Pancreatic

CTSU RTOG-0848

  • A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of PancreasAdenocarcinoma


Clinical Trials: Prevention

CTSU S0820

  • A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers s/p one year after primary resection in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)


Registries:

P Registry

  • Breast Cancer Collaborative Registry (BCCR) for patients who have breast cancer that has been recently diagnosed, have a history of breast cancer, or are at high risk of developing breast cancer, or because relatives have been diagnosed with breast cancer.

P Registry

  • informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia